Cargando…
Application of PD-1 Blockade in Cancer Immunotherapy
The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy. Application of anti...
Autores principales: | Wu, Xiaomo, Gu, Zhongkai, Chen, Yang, Chen, Borui, Chen, Wei, Weng, Liqiang, Liu, Xiaolong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558092/ https://www.ncbi.nlm.nih.gov/pubmed/31205619 http://dx.doi.org/10.1016/j.csbj.2019.03.006 |
Ejemplares similares
-
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015) -
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017) -
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
por: Wu, Xiaomo, et al.
Publicado: (2020) -
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
por: Wu, Yilun, et al.
Publicado: (2019) -
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)